Atypical radiographic changes seen in dogs treated with bedinvetmab (Librela)

The purpose of this study was to describe adverse clinical and radiographic musculoskeletal findings in dogs treated with bedinvetmab (Librela).

Musculoskeletal adverse events in dogs treated with bedinvetmab were obtained from the Zoetis Global Pharmacovigilance database. Case inclusion criteria were adverse event reports that contained a minimum amount of medical information to allow for interpretation of the case along with radiographs or radiology reports. Following initial review, cases were assigned to one of the following categories: (a) insufficient information; (b) consistent with normal progression of osteoarthritis; (c) consistent with other specific orthopedic disease; or (d) atypical findings. Category (d) cases went through a second review, in which they were assigned to descriptive categories based on radiographic changes.

During the study period (November 2020 through December 2025), 319 cases were considered as potential cases of adverse musculoskeletal events. Review of these cases found 186 that had atypical radiographic findings. Abnormal periarticular bone remodeling was the most common change noted, but other significant changes were found. Most commonly, the elbow or tarsus joint was involved. Changes occurred unilaterally or bilaterally and could be progressive and affect different joints in the same dog. Concurrent administration of NSAIDs was reported in 118 dogs (63%), and off-label use of bedinvetmab was reported in 46 dogs (25%).

This study describes the clinical and radiographic features seen following bedinvetmab treatment.

Dogs can exhibit unique clinical and radiographic features when treated with bedinvetmab that can differentiate them from other musculoskeletal conditions.